SCHEMBL8619830

SCHEMBL8619830

COc1ccccc1OC(CCC(P(=O)(O)O)S(=O)(=O)O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.52
SLC6A4 P31645 5/20 0.52
CYP1A2 P05177 4/20 0.52
CYP3A4 P08684 4/20 0.52
CYP2D6 P10635 4/20 0.52
KMT2A Q03164 3/20 0.52
TSHR P16473 3/20 0.52
SLC6A3 Q01959 3/20 0.52
MEN1 O00255 1/20 0.52
CYP2C19 P33261 1/20 0.52
PMP22 Q01453 2/20 0.51
SLC6A9 P48067 2/20 0.48
ACP3 P15309 1/20 0.39
CHRM1 P11229 2/20 0.38
ADRA2B P18089 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HRH1 P35367 2/20 0.38
OPRM1 P35372 2/20 0.38
DRD3 P35462 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8622280 0.88 SLC6A2 (0.52) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL8623971 0.85 PPARG (0.39) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL8623419 0.83 SLC6A4 (0.46) SLC6A2SLC6A4SLC6A3SLC6A9ACP3
SCHEMBL8623463 0.82 ACP3 (0.34) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL8626313 0.81 ACP3 (0.39) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL8622068 0.81 SLC6A9 (0.48) SLC6A4KMT2AMEN1SLC6A9ACP3
SCHEMBL8621492 0.78 ACP3 (0.44) SLC6A4KMT2AMEN1SLC6A9ACP3
SCHEMBL8620195 0.77 F2 (0.39) SLC6A4SLC6A9ACP3
SCHEMBL8622245 0.74 SLC6A2 (0.48) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL8623278 0.74 FDFT1 (0.42) SLC6A4ACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US claimed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US claimed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP claimed
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US disclosed
US-5567841-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-22 US disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP disclosed